| Year |
Citation |
Score |
| 2021 |
Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer. PMID 33539540 DOI: 10.1200/Jco.2019.37.15_Suppl.3118 |
0.658 |
|
| 2020 |
van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen J, Bernards R, Schellens J. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The Oncologist. 26: 290-e545. PMID 33296125 DOI: 10.1002/onco.13631 |
0.61 |
|
| 2020 |
Huijberts S, Wang L, de Oliveira RL, Rosing H, Nuijen B, Beijnen J, Bernards R, Schellens J, Wilgenhof S. Vorinostat in patients with resistant mutated advanced melanoma: a proof of concept study. Future Oncology (London, England). PMID 32125175 DOI: 10.2217/Fon-2020-0023 |
0.394 |
|
| 2018 |
van Andel L, Rosing H, Schellens JH, Beijnen JH. Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. Marine Drugs. 16. PMID 30041477 DOI: 10.3390/Md16070246 |
0.38 |
|
| 2018 |
Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, et al. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. PMID 29882016 DOI: 10.1007/S00280-018-3610-Z |
0.372 |
|
| 2017 |
Henricks LM, Siemerink EJ, Rosing H, Meijer J, Goorden SM, Polstra AM, Zoetekouw L, Cats A, Schellens JH, van Kuilenburg AB. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. International Journal of Cancer. PMID 28929491 DOI: 10.1002/Ijc.31065 |
0.411 |
|
| 2017 |
van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. Jmir Research Protocols. 6: e136. PMID 28705789 DOI: 10.2196/resprot.7790 |
0.51 |
|
| 2017 |
van Geel RM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema M, Faris JE, Eskens FA, Sharma S, Yaeger R, Lenz HJ, ... ... Schellens JH, et al. A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discovery. PMID 28363909 DOI: 10.1158/2159-8290.Cd-16-0795 |
0.375 |
|
| 2017 |
de Jonge M, de Weger VA, Dickson MA, Langenberg M, Le Cesne A, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, Thomas K, Schellens JH. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. European Journal of Cancer (Oxford, England : 1990). 76: 144-151. PMID 28324749 DOI: 10.1016/J.Ejca.2017.02.005 |
0.355 |
|
| 2017 |
van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investigational New Drugs. PMID 28303528 DOI: 10.1007/S10637-017-0451-2 |
0.519 |
|
| 2017 |
Workman P, Draetta GF, Schellens JH, Bernards R. How Much Longer Will We Put Up With $100,000 Cancer Drugs? Cell. 168: 579-583. PMID 28187281 DOI: 10.1016/J.Cell.2017.01.034 |
0.321 |
|
| 2017 |
Verheijen RB, Beijnen JH, Schellens JH, Huitema AD, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clinical Pharmacokinetics. PMID 28185218 DOI: 10.1007/S40262-017-0510-Z |
0.645 |
|
| 2017 |
Nijenhuis CM, Lucas L, Rosing H, Huitema AD, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JH, Beijnen JH. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Investigational New Drugs. PMID 28138829 DOI: 10.1007/S10637-017-0428-1 |
0.524 |
|
| 2017 |
van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AH, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-Plitidepsin in patients with advanced cancer. Investigational New Drugs. PMID 28111728 DOI: 10.1007/S10637-017-0432-5 |
0.496 |
|
| 2017 |
Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies. Drug Development and Industrial Pharmacy. 43: 584-594. PMID 28010129 DOI: 10.1080/03639045.2016.1274901 |
0.418 |
|
| 2017 |
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JH, Soria J, Wen PY, Zielinski C, Urbanowitz G, Mookerjee B, Wang D, Rangwala FA, Keam B. Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC). Journal of Clinical Oncology. 35: 6023-6023. DOI: 10.1200/Jco.2017.35.15_Suppl.6023 |
0.307 |
|
| 2017 |
Schellens JH, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. Journal of Clinical Oncology. 35: 5514-5514. DOI: 10.1200/Jco.2017.35.15_Suppl.5514 |
0.344 |
|
| 2017 |
van Bussel M, Mau-Soerensen M, Damstrup L, Nielsen D, Verheul HM, Aftimos PG, De Jonge MJ, Berghoff K, Schellens JH. A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors. Journal of Clinical Oncology. 35: 2556-2556. DOI: 10.1200/Jco.2017.35.15_Suppl.2556 |
0.352 |
|
| 2017 |
Alsina M, Boni V, Schellens JH, Moreno V, Bol K, Westendorp M, Sirulnik LA, Tabernero J, Calvo E. First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 35: 2522-2522. DOI: 10.1200/Jco.2017.35.15_Suppl.2522 |
0.357 |
|
| 2017 |
Verheijen RB, van Duijl TT, van den Heuvel MM, Beijnen JH, Schellens JH, van den Broek D, Steeghs N, Huitema A. Monitoring of circulating tumor DNA in non-small cell lung cancer patients treated with EGFR-inhibitors. Journal of Clinical Oncology. 35: 11535-11535. DOI: 10.1200/Jco.2017.35.15_Suppl.11535 |
0.435 |
|
| 2017 |
van Bussel M, Pluim D, Milojkovic-Kerklaan B, van den Broek D, Beijnen J, Boogerd W, Schellens J, Rhun EL, Brandsma D. CMET-12. TUMOR CELL DETECTION BY IMMUNOFLOW CYTOMETRY AND BRAF MUTATION ANALYSIS IN CEREBROSPINAL FLUID OF MELANOMA PATIENTS WITH SUSPECTED LEPTOMENINGEAL METASTASES Neuro-Oncology. 19: vi41-vi41. DOI: 10.1093/Neuonc/Nox168.161 |
0.393 |
|
| 2017 |
Herbrink M, Schellens J, Beijnen J, Nuijen B. Thermal study of pazopanib hydrochloride Journal of Thermal Analysis and Calorimetry. 130: 1491-1499. DOI: 10.1007/S10973-017-6286-4 |
0.4 |
|
| 2016 |
de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH. Fast and adequate liquid chromatography-tandem mass spectrometric determination of Z-endoxifen serum levels for therapeutic drug monitoring. Therapeutic Drug Monitoring. PMID 28045782 DOI: 10.1097/Ftd.0000000000000372 |
0.484 |
|
| 2016 |
Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JH. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4354-4361. PMID 27998224 DOI: 10.1200/Jco.2016.67.5942 |
0.469 |
|
| 2016 |
van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1040: 14-21. PMID 27898364 DOI: 10.1016/J.Jchromb.2016.11.020 |
0.488 |
|
| 2016 |
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016672048. PMID 27870574 DOI: 10.1200/Jco.2016.67.2048 |
0.388 |
|
| 2016 |
Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research. PMID 27864786 DOI: 10.1007/S13346-016-0346-3 |
0.667 |
|
| 2016 |
Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treatment Reviews. 50: 247-263. PMID 27776286 DOI: 10.1016/J.Ctrv.2016.09.012 |
0.462 |
|
| 2016 |
Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic Drug Monitoring. 38: 649-656. PMID 27749781 DOI: 10.1097/Ftd.0000000000000349 |
0.647 |
|
| 2016 |
Bins S, Cirkel GA, Gadellaa-van Hooijdonk CG, Weeber F, Nijman IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, ... ... Schellens JH, et al. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. The Oncologist. PMID 27662884 DOI: 10.1634/Theoncologist.2016-0085 |
0.308 |
|
| 2016 |
Sparidans RW, Rosing H, Rood JJ, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1033: 390-398. PMID 27639128 DOI: 10.1016/J.Jchromb.2016.09.012 |
0.451 |
|
| 2016 |
Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, et al. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27601554 DOI: 10.1200/Jco.2016.67.5991 |
0.328 |
|
| 2016 |
Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treatment Reviews. 50: 23-34. PMID 27589829 DOI: 10.1016/J.Ctrv.2016.08.002 |
0.459 |
|
| 2016 |
Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JH. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemotherapy and Pharmacology. PMID 27544765 DOI: 10.1007/S00280-016-3137-0 |
0.393 |
|
| 2016 |
Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clinical Pharmacokinetics. PMID 27534647 DOI: 10.1007/S40262-016-0443-Y |
0.642 |
|
| 2016 |
Sawicki E, Beijnen JH, Schellens JH, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. International Journal of Pharmaceutics. PMID 27480397 DOI: 10.1016/J.Ijpharm.2016.07.068 |
0.439 |
|
| 2016 |
Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27470967 DOI: 10.1158/1078-0432.Ccr-16-1255 |
0.66 |
|
| 2016 |
Rood JJ, van Bussel MT, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1031: 80-85. PMID 27469903 DOI: 10.1016/J.Jchromb.2016.07.037 |
0.47 |
|
| 2016 |
Rood JJ, Schellens JH, Beijnen JH, Sparidans RW. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis. PMID 27460293 DOI: 10.1016/J.Jpba.2016.06.037 |
0.456 |
|
| 2016 |
van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. The Oncologist. PMID 27440064 DOI: 10.1634/Theoncologist.2016-0061 |
0.442 |
|
| 2016 |
Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. Journal of Clinical Pharmacology. PMID 27365214 DOI: 10.1002/Jcph.788 |
0.469 |
|
| 2016 |
Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials. 17: 293. PMID 27323902 DOI: 10.1186/S13063-016-1423-0 |
0.314 |
|
| 2016 |
Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, ... ... Schellens JH, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer. Cancer Research. PMID 27312529 DOI: 10.1158/0008-5472.Can-16-0396 |
0.318 |
|
| 2016 |
Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, Beijnen JH. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1027: 1-10. PMID 27236532 DOI: 10.1016/J.Jchromb.2016.05.016 |
0.464 |
|
| 2016 |
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, et al. The Time To Progression Ratio: a new individualized volumetric parameter for early detection of clinical benefit of targeted therapies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27234642 DOI: 10.1093/Annonc/Mdw223 |
0.331 |
|
| 2016 |
Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P, Rosing H, Spiegelstein O, Schellens JH. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. Investigational New Drugs. PMID 27221729 DOI: 10.1007/S10637-016-0360-9 |
0.678 |
|
| 2016 |
Nijenhuis CM, Schellens JH, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews. 48: 266-80. PMID 27186889 DOI: 10.1080/03602532.2016.1181081 |
0.419 |
|
| 2016 |
Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1023: 24-29. PMID 27179188 DOI: 10.1016/J.Jchromb.2016.04.049 |
0.473 |
|
| 2016 |
Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JH, Beijnen JH. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 126: 75-82. PMID 27179185 DOI: 10.1016/J.Jpba.2016.04.039 |
0.445 |
|
| 2016 |
Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH. Reply to T. Magnes et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27161961 DOI: 10.1200/Jco.2016.67.4374 |
0.315 |
|
| 2016 |
Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. British Journal of Clinical Pharmacology. PMID 27161955 DOI: 10.1111/Bcp.13007 |
0.714 |
|
| 2016 |
Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemotherapy and Pharmacology. PMID 27103124 DOI: 10.1007/S00280-016-3035-5 |
0.61 |
|
| 2016 |
Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100]. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1020: 168-169. PMID 27063483 DOI: 10.1016/J.Jchromb.2016.03.016 |
0.408 |
|
| 2016 |
Nijenhuis CM, Haverkate H, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 125: 270-9. PMID 27058232 DOI: 10.1016/J.Jpba.2016.03.049 |
0.487 |
|
| 2016 |
Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, ... Schellens JH, et al. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs. 34: 329-37. PMID 27039386 DOI: 10.1007/S10637-016-0344-9 |
0.357 |
|
| 2016 |
Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S, Critchley D, Shumaker R, Schellens JH, Beijnen JH. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. Investigational New Drugs. PMID 27018262 DOI: 10.1007/S10637-016-0342-Y |
0.47 |
|
| 2016 |
Nijenhuis CM, Lucas L, Rosing H, Robertson P, Hellriegel ET, Schellens JH, Beijnen AJ. Metabolite profiling of (14)C-omacetaxine mepesuccinate in plasma and excreta of cancer patients. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-11. PMID 26998885 DOI: 10.3109/00498254.2016.1152418 |
0.413 |
|
| 2016 |
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, ... Schellens JH, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer. PMID 26970343 DOI: 10.1002/Cncr.29864 |
0.425 |
|
| 2016 |
van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26960536 DOI: 10.1007/S10928-016-9466-0 |
0.448 |
|
| 2016 |
Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology. PMID 26918324 DOI: 10.1002/Jcph.728 |
0.64 |
|
| 2016 |
de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. European Journal of Clinical Pharmacology. PMID 26915815 DOI: 10.1007/S00228-016-2030-4 |
0.479 |
|
| 2016 |
van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA. Crizotinib-induced fatal fulminant liver failure. Lung Cancer (Amsterdam, Netherlands). 93: 17-9. PMID 26898609 DOI: 10.1016/J.Lungcan.2015.12.010 |
0.593 |
|
| 2016 |
Sparidans RW, van Hoppe S, Rood JJ, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1012: 118-123. PMID 26826475 DOI: 10.1016/J.Jchromb.2016.01.025 |
0.464 |
|
| 2016 |
Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International Journal of Cancer. Journal International Du Cancer. PMID 26804235 DOI: 10.1002/Ijc.30014 |
0.392 |
|
| 2016 |
Cirkel GA, Kerklaan BM, Vanhoutte F, der Aa AV, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, Voest EE, Schellens JH, Lolkema MP. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Investigational New Drugs. PMID 26792581 DOI: 10.1007/S10637-015-0320-9 |
0.393 |
|
| 2016 |
Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP. Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection. Antimicrobial Agents and Chemotherapy. PMID 26787691 DOI: 10.1128/Aac.02976-15 |
0.428 |
|
| 2016 |
Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. European Journal of Cancer (Oxford, England : 1990). 54: 120-130. PMID 26761784 DOI: 10.1016/J.Ejca.2015.10.013 |
0.727 |
|
| 2016 |
Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers. 8. PMID 26729170 DOI: 10.3390/Cancers8010006 |
0.647 |
|
| 2016 |
Subbiah V, Bang Y, Lassen UN, Wainberg ZA, Soria J, Wen PY, Zenz T, Moreau P, Brunsvig P, De Braud FG, De Greve J, De Jonge MJ, Hofheinz RD, Italiano A, Stein A, ... ... Schellens JH, et al. ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy. Journal of Clinical Oncology. 34: TPS2604-TPS2604. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2604 |
0.31 |
|
| 2016 |
Tabernero J, Geel RV, Guren TK, Yaeger RD, Spreafico A, Faris JE, Yoshino T, Yamada Y, Kim TW, Bendell JC, Schuler MH, Lenz H, Eskens F, Desai J, Hochster HS, ... ... Schellens JH, et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). Journal of Clinical Oncology. 34: 3544-3544. DOI: 10.1200/Jco.2016.34.15_Suppl.3544 |
0.327 |
|
| 2015 |
Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. British Journal of Clinical Pharmacology. PMID 26718616 DOI: 10.1111/Bcp.12877 |
0.619 |
|
| 2015 |
Lunenburg CA, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JH, Gelderblom H. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. European Journal of Cancer (Oxford, England : 1990). 54: 40-48. PMID 26716401 DOI: 10.1016/J.Ejca.2015.11.008 |
0.35 |
|
| 2015 |
Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. PMID 26652864 DOI: 10.4155/Bio.15.235 |
0.638 |
|
| 2015 |
Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, ... ... Schellens JH, et al. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs. PMID 26643663 DOI: 10.1007/S10637-015-0309-4 |
0.434 |
|
| 2015 |
van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports. 11: 335-344. PMID 26617477 DOI: 10.1007/S11888-015-0288-Z |
0.424 |
|
| 2015 |
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, ... ... Schellens JH, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology. PMID 26603945 DOI: 10.1016/S1470-2045(15)00286-7 |
0.358 |
|
| 2015 |
Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. The Aaps Journal. PMID 26603889 DOI: 10.1208/S12248-015-9838-1 |
0.63 |
|
| 2015 |
Munster PN, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner T, Dees EC, Bergsland EK, Agarwal N, Kleha JF, Durante M, Adams LM, Smith DA, et al. First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26603258 DOI: 10.1158/1078-0432.Ccr-15-1665 |
0.304 |
|
| 2015 |
Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26573078 DOI: 10.1200/Jco.2015.63.1325 |
0.401 |
|
| 2015 |
Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro-Oncology. PMID 26566655 DOI: 10.1093/Neuonc/Nov273 |
0.376 |
|
| 2015 |
Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. PMID 26547132 DOI: 10.1016/J.Ctrv.2015.10.008 |
0.614 |
|
| 2015 |
Rood JJ, van Hoppe S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 118: 123-131. PMID 26540627 DOI: 10.1016/J.Jpba.2015.10.033 |
0.461 |
|
| 2015 |
Keusters WR, Frederix GW, de Weger VA, Beijnen JH, Hövels AM, Schellens JH. Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (Nsclc). Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A446. PMID 26532512 DOI: 10.1016/J.Jval.2015.09.1113 |
0.377 |
|
| 2015 |
Deenen MJ, Meulendijks D, Boot H, Legdeur MJ, Beijnen JH, Schellens JH, Cats A. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemotherapy and Pharmacology. PMID 26499900 DOI: 10.1007/S00280-015-2872-Y |
0.441 |
|
| 2015 |
Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. Strategies to target drugs to gliomas and CNS metastases of solid tumors. Journal of Neurology. PMID 26477024 DOI: 10.1007/S00415-015-7919-9 |
0.395 |
|
| 2015 |
Meulendijks D, Lassen U, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker D, Hansen A, Simcox ME, Schostack K, Bottino D, Zhong H, Roessler M, Vega-Harring S, Jarutat T, ... ... Schellens JH, et al. Exposure and Tumor Fn14 expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-positive Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446946 DOI: 10.1158/1078-0432.Ccr-15-1506 |
0.553 |
|
| 2015 |
van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, Schellens JH. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational New Drugs. PMID 26362459 DOI: 10.1007/S10637-015-0281-Z |
0.504 |
|
| 2015 |
Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH, Gorman SH, Burke SM, Campbell DA, Chapple MW, Yousey TH, Mulvana DE. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1002: 152-9. PMID 26319804 DOI: 10.1016/J.Jchromb.2015.08.015 |
0.472 |
|
| 2015 |
van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 386-95. PMID 26312162 DOI: 10.1002/psp4.49 |
0.608 |
|
| 2015 |
van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 374-85. PMID 26312161 DOI: 10.1002/psp4.48 |
0.624 |
|
| 2015 |
Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. International Journal of Cancer. Journal International Du Cancer. PMID 26297509 DOI: 10.1002/Ijc.29812 |
0.45 |
|
| 2015 |
Kerklaan BM, Lolkema MP, Devriese LA, Voest EE, Nol-Boekel A, Mergui-Roelvink M, Langenberg M, Mykulowycz K, Stoebenau J, Lane S, Legenne P, Wissel P, Smith DA, Giantonio BJ, Schellens JH, et al. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. British Journal of Cancer. 113: 706-15. PMID 26291057 DOI: 10.1038/Bjc.2015.257 |
0.366 |
|
| 2015 |
Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G>C Substitution in the First 28-bp tandem repeat of the thymidylate synthase 2R Allele. International Journal of Cancer. Journal International Du Cancer. PMID 26189437 DOI: 10.1002/Ijc.29694 |
0.416 |
|
| 2015 |
van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. British Journal of Cancer. 113: 396-402. PMID 26180927 DOI: 10.1038/Bjc.2015.256 |
0.421 |
|
| 2015 |
Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, Schellens JH, Beijnen JH, Dorlo TP. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 998: 57-62. PMID 26160472 DOI: 10.1016/J.Jchromb.2015.06.017 |
0.478 |
|
| 2015 |
Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research & Perspectives. 3: e00131. PMID 26038706 DOI: 10.1002/Prp2.131 |
0.607 |
|
| 2015 |
Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Dried blood spot self-sampling at home for the individualization of tamoxifen treatment: a feasibility study. Therapeutic Drug Monitoring. PMID 26035041 DOI: 10.1097/Ftd.0000000000000224 |
0.355 |
|
| 2015 |
Jager NG, Linn SC, Schellens JH, Beijnen JH. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clinical Breast Cancer. PMID 25997856 DOI: 10.1016/J.Clbc.2015.04.005 |
0.482 |
|
| 2015 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". Biomed Research International. 2015: 124035. PMID 25922829 DOI: 10.1155/2015/124035 |
0.719 |
|
| 2015 |
Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, Schellens JH, Cats A. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British Journal of Cancer. 112: 1358-66. PMID 25871546 DOI: 10.1038/Bjc.2015.20 |
0.348 |
|
| 2015 |
Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis. 7: 519-29. PMID 25826134 DOI: 10.4155/Bio.14.304 |
0.396 |
|
| 2015 |
Kordes S, Klümpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 75: 1135-41. PMID 25822310 DOI: 10.1007/S00280-015-2730-Y |
0.361 |
|
| 2015 |
Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews. 41: 412-422. PMID 25818541 DOI: 10.1016/J.Ctrv.2015.03.005 |
0.454 |
|
| 2015 |
Derissen EJ, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. Journal of Pharmaceutical and Biomedical Analysis. 110: 58-66. PMID 25804433 DOI: 10.1016/J.Jpba.2015.02.051 |
0.464 |
|
| 2015 |
Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75: 763-72. PMID 25677447 DOI: 10.1007/S00280-015-2698-7 |
0.442 |
|
| 2015 |
Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. British Journal of Clinical Pharmacology. PMID 25677219 DOI: 10.1111/Bcp.12606 |
0.631 |
|
| 2015 |
Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. Journal of Pharmaceutical and Biomedical Analysis. 107: 403-8. PMID 25659532 DOI: 10.1016/J.Jpba.2015.01.026 |
0.475 |
|
| 2015 |
Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. European Journal of Clinical Pharmacology. 71: 357-61. PMID 25567218 DOI: 10.1007/S00228-014-1802-Y |
0.601 |
|
| 2015 |
Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Hooiveld MJ, Neven P, Raaijmakers JA, Schellens JH. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. European Journal of Cancer Care. 24: 340-54. PMID 25413216 DOI: 10.1111/Ecc.12266 |
0.578 |
|
| 2015 |
Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology. 79: 809-19. PMID 25393890 DOI: 10.1111/Bcp.12550 |
0.732 |
|
| 2015 |
Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 33: 233-40. PMID 25377392 DOI: 10.1007/S10637-014-0181-7 |
0.672 |
|
| 2015 |
Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrobial Agents and Chemotherapy. 59: 1-14. PMID 25367913 DOI: 10.1128/Aac.04298-14 |
0.42 |
|
| 2015 |
Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drugs. 33: 201-14. PMID 25344453 DOI: 10.1007/S10637-014-0179-1 |
0.454 |
|
| 2015 |
Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. Veterinary and Comparative Oncology. 13: 124-32. PMID 23714139 DOI: 10.1111/Vco.12025 |
0.435 |
|
| 2015 |
Aftimos PG, Milojkovic-Kerklaan B, Diéras V, Altintas S, Anders C, Arnedos M, Gelderblom H, Soetekouw P, Gladdines W, Gaillard P, Sousa Cd, Jager A, Linde Mv, Awada A, Schellens J, et al. Abstract P6-16-04: Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-16-04 |
0.353 |
|
| 2015 |
Elez E, Schellens J, Geel Rv, Bendell J, Spreafico A, Schuler M, Yoshino T, Delord J, Yamada Y, Lolkema M, Faris JE, Eskens F, Sharma S, Yaeger R, Lenz H, et al. LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv262.08 |
0.311 |
|
| 2014 |
Joerger M, Huitema AD, Boot H, Cats A, Doodeman V, Smits P, Vainchtein L, Rosing H, Meijerman I, Zueger M, Cerny TT, Beijnen JH, Schellens J. 1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv548. PMID 28172174 DOI: 10.1093/Annonc/Mdu358.8 |
0.49 |
|
| 2014 |
Lassen UN, Ruiperez AC, Fleitas T, Meulendijks D, Schellens J, Lolkemar M, De Jonge MJ, Sleijfer S, Mau-Soerensen M, Taus A, Adessi C, Keelara A, Michielin F, Bossenmaier B, Meneses-Lorente G, et al. 444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv147. PMID 28170796 DOI: 10.1093/Annonc/Mdu331.4 |
0.348 |
|
| 2014 |
Juric D, Burris H, Schuler M, Schellens J, Berlin J, Seggewiß-Bernhardt R, Gil-Martin M, Gupta A, Rodon J, Tabernero J, Janku F, Rugo HS, Bootle D, Quadt C, Coughlin C, et al. 451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv150. PMID 28170787 DOI: 10.1093/Annonc/Mdu331.11 |
0.342 |
|
| 2014 |
Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. Bioanalysis. 6: 3215-24. PMID 25529888 DOI: 10.4155/Bio.14.171 |
0.397 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Beijnen JH. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 6: 2481-514. PMID 25384597 DOI: 10.4155/Bio.14.185 |
0.404 |
|
| 2014 |
Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, et al. Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5663-71. PMID 25252757 DOI: 10.1200/Jco.2011.29.15_Suppl.3084 |
0.382 |
|
| 2014 |
Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs & Aging. 31: 737-47. PMID 25216600 DOI: 10.1007/S40266-014-0207-Z |
0.601 |
|
| 2014 |
van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatric Blood & Cancer. 61: 2223-9. PMID 25175364 DOI: 10.1002/Pbc.25198 |
0.729 |
|
| 2014 |
Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British Journal of Cancer. 111: 1726-33. PMID 25167226 DOI: 10.1038/Bjc.2014.467 |
0.4 |
|
| 2014 |
Opdam FL, Huitema AD, Beijnen JH, Schellens JH. [Hyperglycaemia during treatment with everolimus]. Nederlands Tijdschrift Voor Geneeskunde. 158: A7544. PMID 25115206 |
0.573 |
|
| 2014 |
Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Investigational New Drugs. 32: 1083-95. PMID 25078948 DOI: 10.1007/S10637-014-0143-0 |
0.458 |
|
| 2014 |
Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4251-61. PMID 24947927 DOI: 10.1158/1078-0432.Ccr-14-0341 |
0.318 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Research and Treatment. 146: 137-44. PMID 24859000 DOI: 10.1007/S10549-014-2999-2 |
0.401 |
|
| 2014 |
Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays. Bioanalysis. 6: 993-1010. PMID 24806907 DOI: 10.4155/Bio.14.48 |
0.439 |
|
| 2014 |
van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Investigational New Drugs. 32: 913-27. PMID 24788562 DOI: 10.1007/S10637-014-0103-8 |
0.724 |
|
| 2014 |
Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. British Journal of Cancer. 110: 2669-76. PMID 24781280 DOI: 10.1038/Bjc.2014.222 |
0.449 |
|
| 2014 |
Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. British Journal of Cancer. 110: 2441-9. PMID 24736581 DOI: 10.1038/Bjc.2014.194 |
0.491 |
|
| 2014 |
Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. The Journal of Pharmacy and Pharmacology. 66: 1339-46. PMID 24730468 DOI: 10.1111/Jphp.12259 |
0.461 |
|
| 2014 |
Hendrikx JJ, Lagas JS, Daling R, Hooijberg JH, Schellens JH, Beijnen JH, Brandjes DP, Huitema AD. Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. Basic & Clinical Pharmacology & Toxicology. 115: 472-5. PMID 24717115 DOI: 10.1111/Bcpt.12251 |
0.583 |
|
| 2014 |
van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2059-65. PMID 24713311 DOI: 10.1093/Annonc/Mdu140 |
0.674 |
|
| 2014 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Research International. 2014: 897216. PMID 24672799 DOI: 10.1155/2014/897216 |
0.718 |
|
| 2014 |
Goey AK, Beijnen JH, Schellens JH. Herb-drug interactions in oncology. Clinical Pharmacology and Therapeutics. 95: 354-5. PMID 24646483 DOI: 10.1038/Clpt.2014.18 |
0.395 |
|
| 2014 |
de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anti-Cancer Drugs. 25: 488-94. PMID 24637579 DOI: 10.1097/Cad.0000000000000093 |
0.482 |
|
| 2014 |
Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography : Bmc. 28: 1366-70. PMID 24619951 DOI: 10.1002/Bmc.3176 |
0.483 |
|
| 2014 |
Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clinical Pharmacokinetics. 53: 305-25. PMID 24566736 DOI: 10.1007/S40262-014-0137-2 |
0.656 |
|
| 2014 |
Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 92: 144-8. PMID 24518133 DOI: 10.1016/J.Jpba.2014.01.011 |
0.464 |
|
| 2014 |
Guchelaar HJ, Gelderblom H, van der Straaten T, Schellens JH, Swen JJ. Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing. Clinical Pharmacology and Therapeutics. 95: 383-5. PMID 24448475 DOI: 10.1038/Clpt.2014.13 |
0.305 |
|
| 2014 |
Mooiman KD, Maas-Bakker RF, Hendrikx JJ, Bank PC, Rosing H, Beijnen JH, Schellens JH, Meijerman I. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. The Journal of Pharmacy and Pharmacology. 66: 865-74. PMID 24392691 DOI: 10.1111/Jphp.12208 |
0.443 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Research and Treatment. 143: 477-83. PMID 24390246 DOI: 10.1007/S10549-013-2826-1 |
0.491 |
|
| 2014 |
Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Molecular Pharmacology. 85: 520-30. PMID 24334255 DOI: 10.1124/Mol.113.088823 |
0.402 |
|
| 2014 |
Derissen EJ, Hillebrand MJ, Rosing H, Otten HM, Laille E, Schellens JH, Beijnen JH. Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 90: 7-14. PMID 24317024 DOI: 10.1016/J.Jpba.2013.11.010 |
0.45 |
|
| 2014 |
Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. Journal of Pharmaceutical Sciences. 103: 478-84. PMID 24311366 DOI: 10.1002/Jps.23779 |
0.613 |
|
| 2014 |
Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Therapeutic Drug Monitoring. 36: 326-34. PMID 24305627 DOI: 10.1097/Ftd.0000000000000004 |
0.634 |
|
| 2014 |
Frederix GW, van Hasselt JG, Schellens JH, Hövels AM, Raaijmakers JA, Huitema AD, Severens JL. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 32: 47-61. PMID 24263964 DOI: 10.1007/S40273-013-0106-X |
0.692 |
|
| 2014 |
Kloth JS, Klümpen HJ, Yu H, Eechoute K, Samer CF, Kam BL, Huitema AD, Daali Y, Zwinderman AH, Balakrishnar B, Bennink RJ, Wong M, Schellens JH, Mathijssen RH, Gurney H. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clinical Pharmacokinetics. 53: 261-9. PMID 24234588 DOI: 10.1007/S40262-013-0111-4 |
0.601 |
|
| 2014 |
Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Current Clinical Pharmacology. 9: 139-47. PMID 24219005 DOI: 10.2174/1574884708666131111193403 |
0.638 |
|
| 2014 |
Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 630-5. PMID 24216282 DOI: 10.1016/J.Jpba.2013.10.019 |
0.484 |
|
| 2014 |
Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 626-9. PMID 24216281 DOI: 10.1016/J.Jpba.2013.10.016 |
0.466 |
|
| 2014 |
Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, Schellens JH, Gillessen S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemotherapy and Pharmacology. 73: 113-24. PMID 24166106 DOI: 10.1007/S00280-013-2327-2 |
0.497 |
|
| 2014 |
Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 216-20. PMID 24080524 DOI: 10.1016/J.Jpba.2013.08.051 |
0.47 |
|
| 2014 |
Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JH. The effect of St John's wort on the pharmacokinetics of docetaxel. Clinical Pharmacokinetics. 53: 103-10. PMID 24068654 DOI: 10.1007/S40262-013-0102-5 |
0.499 |
|
| 2014 |
Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. Biomedical Chromatography : Bmc. 28: 302-10. PMID 23996474 DOI: 10.1002/Bmc.3021 |
0.49 |
|
| 2014 |
Gaillard PJ, Kerklaan BM, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, Verheul H, Awada A, Schellens J, Brandsma D. Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct216 |
0.338 |
|
| 2014 |
Kerklaan BM, Jager A, Aftimos P, Dieras V, Altintas S, Anders C, Arnedos M, Gelderblom H, Soetekouw P, Gladdines W, Gaillard P, Sousa Cd, Awada A, Schellens J, Linde Mv, et al. Nt-23Phase 1/2A Study Of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) In Breast Cancer Patients With Brain Metastases (Bcbm) Or Recurrent High Grade Gliomas (Hgg) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou265.21 |
0.362 |
|
| 2014 |
Brandsma D, Kerklaan BM, Diéras V, Altintas S, Anders C, Ballester MA, Gelderblom H, Soetekouw P, Gladdines W, Lonnqvist F, Jager A, van Linde M, Schellens J, Aftimos P. Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg) Annals of Oncology. 25: iv157. DOI: 10.1093/Annonc/Mdu331.32 |
0.312 |
|
| 2014 |
de Weger V, Lolkema M, Dickson M, Le Cesne A, Wagner A, Merqui-Roelvink M, Varga A, Tap W, Schwartz G, Demetri G, Zheng W, Tuffal G, Mace S, Miao H, Schellens J, et al. 378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies European Journal of Cancer. 50: 121-122. DOI: 10.1016/S0959-8049(14)70504-0 |
0.302 |
|
| 2013 |
Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Delivery and Translational Research. 3: 243-51. PMID 25788133 DOI: 10.1007/S13346-012-0127-6 |
0.673 |
|
| 2013 |
Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. Bmc Cancer. 13: 612. PMID 24373320 DOI: 10.1186/1471-2407-13-612 |
0.627 |
|
| 2013 |
Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 940: 121-5. PMID 24145016 DOI: 10.1016/J.Jchromb.2013.09.020 |
0.482 |
|
| 2013 |
Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry. Veterinary and Comparative Oncology. PMID 24034226 DOI: 10.1111/Vco.12049 |
0.442 |
|
| 2013 |
Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. European Journal of Clinical Pharmacology. 69: 2065-72. PMID 23995862 DOI: 10.1007/S00228-013-1579-4 |
0.626 |
|
| 2013 |
Hendrikx JJ, Dubbelman AC, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 27: 1925-34. PMID 23939959 DOI: 10.1002/Rcm.6654 |
0.446 |
|
| 2013 |
Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 934: 22-5. PMID 23892825 DOI: 10.1016/J.Jchromb.2013.06.030 |
0.464 |
|
| 2013 |
Goey AK, Meijerman I, Beijnen JH, Schellens JH. The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. European Journal of Clinical Pharmacology. 69: 1883-90. PMID 23881421 DOI: 10.1007/S00228-013-1558-9 |
0.427 |
|
| 2013 |
Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. Journal of Ethnopharmacology. 149: 543-9. PMID 23876595 DOI: 10.1016/J.Jep.2013.07.014 |
0.47 |
|
| 2013 |
Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, Schellens JH. A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Journal of Clinical Pharmacology. 53: 878-83. PMID 23775853 DOI: 10.1002/Jcph.108 |
0.424 |
|
| 2013 |
Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. British Journal of Clinical Pharmacology. 76: 467-74. PMID 23701184 DOI: 10.1111/Bcp.12159 |
0.487 |
|
| 2013 |
Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1494-504. PMID 23674609 DOI: 10.1124/Dmd.113.050971 |
0.464 |
|
| 2013 |
Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, Schellens JH, Meijerman I. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. Biomedical Chromatography : Bmc. 27: 1107-16. PMID 23674377 DOI: 10.1002/Bmc.2913 |
0.435 |
|
| 2013 |
Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. The Oncologist. 18: 619-24. PMID 23671007 DOI: 10.1634/Theoncologist.2012-0465 |
0.41 |
|
| 2013 |
Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecologic Oncology. 130: 511-7. PMID 23665458 DOI: 10.1016/J.Ygyno.2013.05.001 |
0.665 |
|
| 2013 |
Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: old drugs, new oral formulations. European Journal of Pharmacology. 717: 40-6. PMID 23660368 DOI: 10.1016/J.Ejphar.2013.02.058 |
0.476 |
|
| 2013 |
Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Raaijmakers JA, Schellens JH. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 139: 489-95. PMID 23645005 DOI: 10.1007/S10549-013-2532-Z |
0.562 |
|
| 2013 |
van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. British Journal of Clinical Pharmacology. 76: 412-24. PMID 23601153 DOI: 10.1111/Bcp.12143 |
0.753 |
|
| 2013 |
van Hasselt JG, van Eijkelenburg NK, Huitema AD, Schellens JH, Schouten-van Meeteren AY. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrobial Agents and Chemotherapy. 57: 2878-81. PMID 23571545 DOI: 10.1128/Aac.00068-13 |
0.702 |
|
| 2013 |
Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 117-23. PMID 23542607 DOI: 10.1016/J.Jchromb.2013.02.034 |
0.407 |
|
| 2013 |
Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 124-8. PMID 23537694 DOI: 10.1016/J.Jchromb.2013.02.025 |
0.463 |
|
| 2013 |
Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. International Journal of Radiation Oncology, Biology, Physics. 85: e201-7. PMID 23517808 DOI: 10.1016/J.Ijrobp.2012.12.008 |
0.466 |
|
| 2013 |
Frederix GW, van Hasselt JG, Severens JL, Hövels AM, Huitema AD, Raaijmakers JA, Schellens JH. Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 780-92. PMID 23515213 DOI: 10.1177/0272989X13476763 |
0.675 |
|
| 2013 |
Lankheet NA, Steeghs N, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Therapeutic Drug Monitoring. 35: 168-76. PMID 23503442 DOI: 10.1097/Ftd.0B013E31827Efd9E |
0.481 |
|
| 2013 |
da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. European Journal of Cancer (Oxford, England : 1990). 49: 1654-61. PMID 23481513 DOI: 10.1016/J.Ejca.2013.01.015 |
0.328 |
|
| 2013 |
Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2084-95. PMID 23461902 DOI: 10.1158/1078-0432.Ccr-12-3105 |
0.418 |
|
| 2013 |
van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews. 39: 664-72. PMID 23434072 DOI: 10.1016/J.Ctrv.2013.01.003 |
0.435 |
|
| 2013 |
Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clinical Pharmacokinetics. 52: 399-414. PMID 23420518 DOI: 10.1007/S40262-013-0040-2 |
0.477 |
|
| 2013 |
Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treatment Reviews. 39: 773-83. PMID 23394826 DOI: 10.1016/J.Ctrv.2012.12.008 |
0.477 |
|
| 2013 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Therapeutic Advances in Medical Oncology. 5: 91-2. PMID 23323150 DOI: 10.1177/1758834012464806 |
0.456 |
|
| 2013 |
Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P, Beijnen JH, Schellens JH. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs in R&D. 13: 17-28. PMID 23322528 DOI: 10.1007/S40268-012-0001-5 |
0.518 |
|
| 2013 |
Pluim D, Jacobs BA, Krähenbühl MD, Ruijter AE, Beijnen JH, Schellens JH. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. Analytical and Bioanalytical Chemistry. 405: 2391-5. PMID 23318760 DOI: 10.1007/S00216-012-6614-2 |
0.386 |
|
| 2013 |
Pluim D, Schilders KA, Jacobs BA, Vaartjes D, Beijnen JH, Schellens JH. Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. Analytical and Bioanalytical Chemistry. 405: 2495-503. PMID 23314484 DOI: 10.1007/S00216-012-6676-1 |
0.406 |
|
| 2013 |
Deenen MJ, Rosing H, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 913: 30-40. PMID 23270936 DOI: 10.1016/J.Jchromb.2012.11.033 |
0.495 |
|
| 2013 |
Meulenaar J, Beijnen JH, Schellens JH, Nuijen B. Slow dissolution behaviour of amorphous capecitabine. International Journal of Pharmaceutics. 441: 213-7. PMID 23219704 DOI: 10.1016/J.Ijpharm.2012.11.041 |
0.392 |
|
| 2013 |
Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer. Journal International Du Cancer. 132: 2439-47. PMID 23090875 DOI: 10.1002/Ijc.27912 |
0.416 |
|
| 2013 |
Milojkovic Kerklaan B, Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemotherapy and Pharmacology. 71: 53-62. PMID 23053259 DOI: 10.1007/s00280-012-1972-1 |
0.622 |
|
| 2013 |
Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography : Bmc. 27: 466-76. PMID 22987603 DOI: 10.1002/Bmc.2814 |
0.487 |
|
| 2013 |
Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology. 75: 507-15. PMID 22803519 DOI: 10.1111/J.1365-2125.2012.04381.X |
0.678 |
|
| 2013 |
Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel European Journal of Pharmaceutics and Biopharmaceutics. 83: 87-94. DOI: 10.1016/J.Ejpb.2012.09.016 |
0.488 |
|
| 2012 |
Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, Schellens JH. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. Nederlands Tijdschrift Voor Geneeskunde. 156: A4934. PMID 23191966 |
0.389 |
|
| 2012 |
Lankheet NA, Schaake EE, Rosing H, Burgers JA, Schellens JH, Beijnen JH, Huitema AD. Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue. Bioanalysis. 4: 2563-77. PMID 23173792 DOI: 10.4155/Bio.12.235 |
0.418 |
|
| 2012 |
Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. 83: 87-94. PMID 23085332 DOI: 10.1016/j.ejpb.2012.09.016 |
0.626 |
|
| 2012 |
Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 653-63. PMID 23010851 DOI: 10.1007/S00280-012-1947-2 |
0.503 |
|
| 2012 |
Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 905: 150-4. PMID 22940474 DOI: 10.1016/J.Jchromb.2012.08.021 |
0.463 |
|
| 2012 |
Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, et al. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. British Journal of Cancer. 107: 1025-30. PMID 22910320 DOI: 10.1038/Bjc.2012.371 |
0.337 |
|
| 2012 |
Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clinical Pharmacokinetics. 51: 607-17. PMID 22804749 DOI: 10.1007/Bf03261934 |
0.669 |
|
| 2012 |
Goey AK, Rosing H, Meijerman I, Sparidans RW, Schellens JH, Beijnen JH. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 902: 151-6. PMID 22770780 DOI: 10.1016/J.Jchromb.2012.06.022 |
0.438 |
|
| 2012 |
Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4794-805. PMID 22767668 DOI: 10.1158/1078-0432.Ccr-12-0868 |
0.348 |
|
| 2012 |
van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. The Oncologist. 17: 1081-9. PMID 22733795 DOI: 10.1634/Theoncologist.2012-0055 |
0.458 |
|
| 2012 |
Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. The Aaps Journal. 14: 601-11. PMID 22648902 DOI: 10.1208/S12248-012-9373-2 |
0.589 |
|
| 2012 |
van Hasselt JG, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema AD. Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. Journal of Palliative Care. 28: 60-1. PMID 22582474 |
0.694 |
|
| 2012 |
Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 106: 1598-604. PMID 22516948 DOI: 10.1038/Bjc.2012.154 |
0.441 |
|
| 2012 |
Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH. Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202). The Oncologist. 17: 740-1; author reply . PMID 22511266 DOI: 10.1634/Theoncologist.2011-0413 |
0.469 |
|
| 2012 |
Dubbelman AC, Jansen RS, Rosing H, Darwish M, Hellriegel E, Robertson P, Schellens JH, Beijnen JH. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1297-307. PMID 22492615 DOI: 10.1124/Dmd.112.045229 |
0.436 |
|
| 2012 |
Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. The Oncologist. 17: 536-42. PMID 22477724 DOI: 10.1634/Theoncologist.2011-0461 |
0.414 |
|
| 2012 |
Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 169-73. PMID 22476055 DOI: 10.1016/J.Jchromb.2012.03.020 |
0.471 |
|
| 2012 |
Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 174-7. PMID 22476054 DOI: 10.1016/J.Jchromb.2012.03.021 |
0.459 |
|
| 2012 |
Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 893: 92-100. PMID 22426286 DOI: 10.1016/J.Jchromb.2012.02.039 |
0.473 |
|
| 2012 |
Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Research and Treatment. 133: 793-8. PMID 22388692 DOI: 10.1007/S10549-012-2000-1 |
0.426 |
|
| 2012 |
Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 144-7. PMID 22386128 DOI: 10.1016/J.Jchromb.2012.02.010 |
0.464 |
|
| 2012 |
Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacology. 69: 1457-66. PMID 22382880 DOI: 10.1007/S00280-012-1850-X |
0.425 |
|
| 2012 |
Keizer RJ, Gupta A, Shumaker R, Beijnen JH, Schellens JH, Huitema AD. Model-based treatment optimization of a novel VEGFR inhibitor. British Journal of Clinical Pharmacology. 74: 315-26. PMID 22295876 DOI: 10.1111/J.1365-2125.2012.04197.X |
0.651 |
|
| 2012 |
Vermaat JS, Gerritse FL, Van Der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients European Urology. 62: 685-696. PMID 22285764 DOI: 10.1016/J.Eururo.2012.01.020 |
0.354 |
|
| 2012 |
Dubbelman AC, Rosing H, Schellens JH, Beijnen JH. Bioanalytical aspects of clinical mass balance studies in oncology. Bioanalysis. 3: 2637-55. PMID 22136052 DOI: 10.4155/Bio.11.276 |
0.448 |
|
| 2012 |
Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 313-21. PMID 22041109 DOI: 10.1124/Dmd.111.042762 |
0.668 |
|
| 2012 |
Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 118: 2466-75. PMID 22031394 DOI: 10.1002/Cncr.26562 |
0.624 |
|
| 2012 |
Joerger M, Ferreri AJ, Krähenbühl S, Schellens JH, Cerny T, Zucca E, Huitema AD. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British Journal of Clinical Pharmacology. 73: 240-7. PMID 21838788 DOI: 10.1111/J.1365-2125.2011.04084.X |
0.603 |
|
| 2012 |
Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Investigational New Drugs. 30: 1519-30. PMID 21626115 DOI: 10.1007/S10637-011-9694-5 |
0.646 |
|
| 2012 |
Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemotherapy and Pharmacology. 69: 25-33. PMID 21590444 DOI: 10.1007/S00280-011-1670-4 |
0.494 |
|
| 2012 |
Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. Journal of Clinical Pharmacology. 52: 370-80. PMID 21505085 DOI: 10.1177/0091270010397051 |
0.478 |
|
| 2012 |
Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clinical Drug Investigation. 15: 327-35. PMID 18370488 DOI: 10.2165/00044011-199815040-00009 |
0.449 |
|
| 2012 |
van Hasselt JC, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema A. Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer Journal of Palliative Care. 28: 60-61. DOI: 10.1177/082585971202800110 |
0.624 |
|
| 2011 |
Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema A, Beijnen JH, Schellens JH. Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7536. PMID 28023228 DOI: 10.1200/Jco.2011.29.15_Suppl.7536 |
0.344 |
|
| 2011 |
Schellens JH, Shapiro G, Pavlick AC, Tibes R, Leijen S, Tolaney SM, Diaz-Padilla I, Ramanathan RK, Demuth T, Viscusi J, Cheng JD, Lam R, Xu Y, Oza AM. Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3068. PMID 28022575 DOI: 10.1200/Jco.2011.29.15_Suppl.3068 |
0.308 |
|
| 2011 |
Devriese LA, Witteveen P, Voest EE, Overkleeft EN, Langenberg M, Beijnen JH, Reyderman L, Wanders J, Mould DR, Gupta A, Hussein Z, Schellens JH. Eribulin dosing in patients with advanced solid tumors and hepatic impairment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2544. PMID 28022319 DOI: 10.1200/jco.2011.29.15_suppl.2544 |
0.362 |
|
| 2011 |
Leijen S, Middleton MR, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen ME, Tessier J, Xu ZX, Shochat E, Walz A, Deutsch J, Blotner S, Lopez Valverde V, Naegelen VM, Schellens JH, et al. Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3017. PMID 28022166 DOI: 10.1200/Jco.2011.29.15_Suppl.3017 |
0.329 |
|
| 2011 |
Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry. 106: 90-9. PMID 22112845 DOI: 10.1016/J.Jinorgbio.2011.09.030 |
0.445 |
|
| 2011 |
Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. Journal of Analytical Toxicology. 35: 558-65. PMID 22004675 DOI: 10.1093/Anatox/35.8.558 |
0.651 |
|
| 2011 |
Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68: 1619-28. PMID 21953275 DOI: 10.1007/S00280-011-1732-7 |
0.339 |
|
| 2011 |
Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 2984-90. PMID 21920826 DOI: 10.1016/J.Jchromb.2011.08.034 |
0.478 |
|
| 2011 |
Gast MC, Zapatka M, van Tinteren H, Bontenbal M, Span PN, Tjan-Heijnen VC, Knol JC, Jimenez CR, Schellens JH, Beijnen JH. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. Journal of Cancer Research and Clinical Oncology. 137: 1773-83. PMID 21913038 DOI: 10.1007/S00432-011-1055-4 |
0.398 |
|
| 2011 |
Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3862-8. PMID 21911720 DOI: 10.1200/Jco.2010.33.1298 |
0.409 |
|
| 2011 |
Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). International Journal of Pharmaceutics. 420: 244-50. PMID 21907780 DOI: 10.1016/J.Ijpharm.2011.08.041 |
0.475 |
|
| 2011 |
Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, Schellens JH, Beijnen JH, Zamboni WC. Allometric scaling of pegylated liposomal anticancer drugs. Journal of Pharmacokinetics and Pharmacodynamics. 38: 653-69. PMID 21863380 DOI: 10.1007/S10928-011-9213-5 |
0.344 |
|
| 2011 |
Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational New Drugs. 30: 1557-65. PMID 21809026 DOI: 10.1007/S10637-011-9723-4 |
0.455 |
|
| 2011 |
Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6071-82. PMID 21753156 DOI: 10.1158/1078-0432.Ccr-11-0353 |
0.481 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. The Oncologist. 16: 1006-20. PMID 21659612 DOI: 10.1634/Theoncologist.2010-0261 |
0.442 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. The Oncologist. 16: 992-1005. PMID 21659608 DOI: 10.1634/Theoncologist.2010-0260 |
0.44 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. The Oncologist. 16: 820-34. PMID 21632461 DOI: 10.1634/Theoncologist.2010-0259 |
0.455 |
|
| 2011 |
Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. The Oncologist. 16: 800-10. PMID 21632460 DOI: 10.1634/theoncologist.2010-0035 |
0.343 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: background, methodology, and clinical adoption of pharmacogenetics. The Oncologist. 16: 811-9. PMID 21632456 DOI: 10.1634/theoncologist.2010-0258 |
0.38 |
|
| 2011 |
Sparidans RW, Martens I, Valkenburg-van Iersel LB, den Hartigh J, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1851-6. PMID 21622034 DOI: 10.1016/J.Jchromb.2011.05.003 |
0.492 |
|
| 2011 |
Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treatment Reviews. 37: 579-89. PMID 21592671 DOI: 10.1016/j.ctrv.2011.04.006 |
0.337 |
|
| 2011 |
Teunissen SF, Jager NG, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1677-85. PMID 21543272 DOI: 10.1016/J.Jchromb.2011.04.011 |
0.465 |
|
| 2011 |
Trotta F, Leufkens HG, Schellens JH, Laing R, Tafuri G. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2266-72. PMID 21537038 DOI: 10.1200/Jco.2010.34.1248 |
0.323 |
|
| 2011 |
Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer (Amsterdam, Netherlands). 74: 310-7. PMID 21529986 DOI: 10.1016/J.Lungcan.2011.03.016 |
0.427 |
|
| 2011 |
Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3455-68. PMID 21498394 DOI: 10.1158/1078-0432.Ccr-10-2209 |
0.373 |
|
| 2011 |
Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, Schellens JH, Beijnen JH. Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1149-55. PMID 21458392 DOI: 10.1016/J.Jchromb.2011.03.021 |
0.473 |
|
| 2011 |
Janssens T, Brouwers EE, de Vos JP, Schellens JH, Beijnen JH. Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry. Journal of Analytical Toxicology. 35: 153-61. PMID 21439151 DOI: 10.1093/Anatox/35.3.153 |
0.436 |
|
| 2011 |
Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. The Aaps Journal. 13: 230-9. PMID 21387147 DOI: 10.1208/S12248-011-9260-2 |
0.344 |
|
| 2011 |
Keizer RJ, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic biomarkers in model-based drug development in oncology. Current Clinical Pharmacology. 6: 30-40. PMID 21235464 DOI: 10.2174/157488411794941368 |
0.647 |
|
| 2011 |
Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1131-9. PMID 21220471 DOI: 10.1158/1078-0432.Ccr-10-1220 |
0.343 |
|
| 2011 |
van den Broek I, Sparidans RW, Engwegen JY, Cats A, Depla AC, Schellens JH, Beijnen JH. Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer. Cancer Biomarkers : Section a of Disease Markers. 7: 109-15. PMID 21178269 DOI: 10.3233/Cbm-2010-0153 |
0.393 |
|
| 2011 |
van den Broek I, Sparidans RW, van Winden AW, Gast MC, van Dulken EJ, Schellens JH, Beijnen JH. The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics. Clinical Applications. 4: 931-9. PMID 21137033 DOI: 10.1002/Prca.201000035 |
0.4 |
|
| 2011 |
Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Computer Methods and Programs in Biomedicine. 101: 72-9. PMID 20627442 DOI: 10.1016/J.Cmpb.2010.04.018 |
0.574 |
|
| 2011 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrometry Reviews. 30: 321-43. PMID 20623700 DOI: 10.1002/Mas.20280 |
0.412 |
|
| 2011 |
Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs. 29: 984-95. PMID 20449627 DOI: 10.1007/S10637-010-9437-Z |
0.632 |
|
| 2011 |
Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, Schellens JH. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. Cancer Chemotherapy and Pharmacology. 67: 137-45. PMID 20229082 DOI: 10.1007/S00280-010-1300-6 |
0.354 |
|
| 2011 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Fundamental & Clinical Pharmacology. 25: 172-85. PMID 20199587 DOI: 10.1111/J.1472-8206.2010.00823.X |
0.408 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics The Oncologist. 16: 811-819. DOI: 10.1634/Theoncologist.2010-0258 |
0.466 |
|
| 2011 |
Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TJ, Schellens JH. Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report Tumori Journal. 97: 109-114. DOI: 10.1177/030089161109700119 |
0.389 |
|
| 2011 |
Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials Cancer Treatment Reviews. 37: 579-589. DOI: 10.1016/J.Ctrv.2011.04.006 |
0.429 |
|
| 2010 |
Helgason HH, Engwegen JY, Zapatka M, Cats A, Boot H, Beijnen JH, Schellens JH. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncology Letters. 1: 327-333. PMID 22966303 DOI: 10.3892/Ol_00000058 |
0.445 |
|
| 2010 |
Klümpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. The Oncologist. 15: 1262-9. PMID 21147869 DOI: 10.1634/Theoncologist.2010-0196 |
0.443 |
|
| 2010 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. Clinical Proteomics. 6: 115-127. PMID 21124649 DOI: 10.1007/S12014-010-9054-Z |
0.43 |
|
| 2010 |
Goey AK, Sparidans RW, Meijerman I, Rosing H, Schellens JH, Beijnen JH. A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 41-8. PMID 21123121 DOI: 10.1016/J.Jchromb.2010.11.007 |
0.448 |
|
| 2010 |
de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs. 30: 443-9. PMID 20963470 DOI: 10.1007/S10637-010-9569-1 |
0.415 |
|
| 2010 |
Janssens T, Brouwers EE, de Vos JP, Schellens JH, Beijnen JH. Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 54: 395-400. PMID 20933356 DOI: 10.1016/J.Jpba.2010.09.014 |
0.43 |
|
| 2010 |
Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2751-9. PMID 20829130 DOI: 10.1016/J.Jchromb.2010.08.015 |
0.474 |
|
| 2010 |
Teunissen SF, Vlaming ML, Rosing H, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2353-62. PMID 20708442 DOI: 10.1016/J.Jchromb.2010.07.012 |
0.444 |
|
| 2010 |
Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics. 37: 347-63. PMID 20652729 DOI: 10.1007/S10928-010-9164-2 |
0.638 |
|
| 2010 |
Goey AK, Schellens JH, Beijnen JH, Huitema AD. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. Nederlands Tijdschrift Voor Geneeskunde. 154: A1155. PMID 20619024 |
0.567 |
|
| 2010 |
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 49: 493-507. PMID 20608753 DOI: 10.2165/11531280-000000000-00000 |
0.625 |
|
| 2010 |
Buikhuisen WA, Burgers JA, Vincent AD, Schellens JH, Beijnen JH, Smit EF, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e482-3; author reply. PMID 20606096 DOI: 10.1200/Jco.2010.29.1559 |
0.421 |
|
| 2010 |
Sparidans RW, van Velsen SG, de Roos MP, Schellens JH, Bruijnzeel-Koomen CA, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2150-4. PMID 20605116 DOI: 10.1016/J.Jchromb.2010.06.011 |
0.46 |
|
| 2010 |
Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. British Journal of Clinical Pharmacology. 69: 465-74. PMID 20573082 DOI: 10.1111/J.1365-2125.2010.03621.X |
0.663 |
|
| 2010 |
van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, Depla AC, Cats A, Schellens JH, Peeters PH, Beijnen JH, van Gils CH. Serum degradome markers for the detection of breast cancer. Journal of Proteome Research. 9: 3781-8. PMID 20557135 DOI: 10.1021/Pr100395S |
0.416 |
|
| 2010 |
Helgason HH, Engwegen JY, Zapatka M, Vincent A, Cats A, Boot H, Beijnen JH, Schellens JH. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncology Reports. 24: 57-64. PMID 20514444 DOI: 10.3892/Or_00000828 |
0.437 |
|
| 2010 |
Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2505-11. PMID 20406939 DOI: 10.1200/Jco.2009.25.1082 |
0.311 |
|
| 2010 |
Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, ... Schellens JH, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2512-9. PMID 20406929 DOI: 10.1200/Jco.2009.26.9589 |
0.323 |
|
| 2010 |
Beijnen JH, Schellens JH. Personalized medicine in oncology: a personal view with myths and facts. Current Clinical Pharmacology. 5: 141-7. PMID 20406176 DOI: 10.2174/157488410791498789 |
0.407 |
|
| 2010 |
Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Current Clinical Pharmacology. 5: 186-91. PMID 20406171 DOI: 10.2174/157488410791498824 |
0.396 |
|
| 2010 |
Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Current Clinical Pharmacology. 5: 192-5. PMID 20406170 DOI: 10.2174/157488410791498798 |
0.421 |
|
| 2010 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Facile small scale synthesis of nucleoside 5'-phosphate mixtures. Nucleosides, Nucleotides & Nucleic Acids. 29: 14-26. PMID 20391189 DOI: 10.1080/15257770903451546 |
0.376 |
|
| 2010 |
Oostendorp RL, Buckle T, Lambert G, Garrigue JS, Beijnen JH, Schellens JH, van Tellingen O. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investigational New Drugs. 29: 768-76. PMID 20390333 DOI: 10.1007/S10637-010-9421-7 |
0.367 |
|
| 2010 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 1085-92. PMID 20356805 DOI: 10.1016/J.Jchromb.2010.03.014 |
0.441 |
|
| 2010 |
Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri AJ. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. British Journal of Cancer. 102: 673-7. PMID 20125159 DOI: 10.1038/Sj.Bjc.6605559 |
0.366 |
|
| 2010 |
Jansen RS, Rosing H, Kromdijk W, ter Heine R, Schellens JH, Beijnen JH. Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 621-7. PMID 20122883 DOI: 10.1016/J.Jchromb.2010.01.002 |
0.333 |
|
| 2010 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 590-602. PMID 20116351 DOI: 10.1016/J.Jchromb.2010.01.011 |
0.435 |
|
| 2010 |
Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Shapiro GI. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 884-94. PMID 19825886 DOI: 10.1093/Annonc/Mdp377 |
0.349 |
|
| 2010 |
Vainchtein LD, Rosing H, Schellens JH, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomedical Chromatography : Bmc. 24: 374-86. PMID 19650151 DOI: 10.1002/Bmc.1302 |
0.476 |
|
| 2010 |
Damen CW, Rosing H, Schellens JH, Beijnen JH. High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature. Biomedical Chromatography : Bmc. 24: 83-90. PMID 19606419 DOI: 10.1002/Bmc.1271 |
0.4 |
|
| 2010 |
Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Investigational New Drugs. 28: 163-70. PMID 19404582 DOI: 10.1007/S10637-009-9244-6 |
0.483 |
|
| 2010 |
Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Investigational New Drugs. 28: 61-75. PMID 19198760 DOI: 10.1007/S10637-008-9216-2 |
0.645 |
|
| 2009 |
Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemotherapy and Pharmacology. 66: 765-71. PMID 20041327 DOI: 10.1007/S00280-009-1221-4 |
0.436 |
|
| 2009 |
Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clinical Pharmacology and Therapeutics. 87: 126-9. PMID 19924122 DOI: 10.1038/Clpt.2009.233 |
0.46 |
|
| 2009 |
Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 4090-6. PMID 19910267 DOI: 10.1016/J.Jchromb.2009.10.024 |
0.46 |
|
| 2009 |
Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6152-9. PMID 19901116 DOI: 10.1200/Jco.2009.22.2273 |
0.309 |
|
| 2009 |
Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. The International Journal of Biological Markers. 24: 130-41. PMID 19787623 DOI: 10.5301/Jbm.2009.3475 |
0.303 |
|
| 2009 |
Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens JH, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3625-30. PMID 19762293 DOI: 10.1016/J.Jchromb.2009.09.001 |
0.477 |
|
| 2009 |
Pluim D, Beijnen JH, Schellens JH, van Tellingen O. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3549-55. PMID 19744901 DOI: 10.1016/J.Jchromb.2009.08.035 |
0.459 |
|
| 2009 |
Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, Schellens JH, Rosing H, Beijnen JH. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. Journal of the American Society For Mass Spectrometry. 20: 2021-33. PMID 19744865 DOI: 10.1016/J.Jasms.2009.07.017 |
0.384 |
|
| 2009 |
Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Human Antibodies. 18: 47-73. PMID 19729801 DOI: 10.3233/Hab-2009-0206 |
0.428 |
|
| 2009 |
Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, Schellens JH. Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. The Oncologist. 14: 944-8. PMID 19726456 DOI: 10.1634/Theoncologist.2009-0111 |
0.664 |
|
| 2009 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 23: 3040-50. PMID 19705384 DOI: 10.1002/Rcm.4212 |
0.424 |
|
| 2009 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Protein versus DNA as a marker for peripheral blood mononuclear cell counting. Analytical and Bioanalytical Chemistry. 395: 863-7. PMID 19685233 DOI: 10.1007/S00216-009-3022-3 |
0.372 |
|
| 2009 |
Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. The Oncologist. 14: 780-93. PMID 19684075 DOI: 10.1634/Theoncologist.2009-0019 |
0.385 |
|
| 2009 |
Teunissen SF, Rosing H, Koornstra RH, Linn SC, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 2519-29. PMID 19589736 DOI: 10.1016/J.Jchromb.2009.06.029 |
0.487 |
|
| 2009 |
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine. 361: 123-34. PMID 19553641 DOI: 10.1056/Nejmoa0900212 |
0.341 |
|
| 2009 |
Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4475-83. PMID 19531625 DOI: 10.1158/1078-0432.Ccr-08-3144 |
0.469 |
|
| 2009 |
Damen CW, Speijer H, Hermens WT, Schellens JH, Rosing H, Beijnen JH. The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. Analytical Biochemistry. 393: 73-9. PMID 19523916 DOI: 10.1016/J.Ab.2009.06.006 |
0.412 |
|
| 2009 |
Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncology Reports. 22: 205-13. PMID 19513525 DOI: 10.3892/Or_00000426 |
0.408 |
|
| 2009 |
Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4228-33. PMID 19509162 DOI: 10.1158/1078-0432.Ccr-08-2944 |
0.64 |
|
| 2009 |
Damen CW, Derissen EJ, Schellens JH, Rosing H, Beijnen JH. The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. Journal of Pharmaceutical and Biomedical Analysis. 50: 861-6. PMID 19487098 DOI: 10.1016/J.Jpba.2009.04.031 |
0.405 |
|
| 2009 |
Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, Beijnen JH, Aarden LA. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Analytical Biochemistry. 391: 114-20. PMID 19464994 DOI: 10.1016/J.Ab.2009.05.030 |
0.431 |
|
| 2009 |
Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 47: 694-705. PMID 19416081 DOI: 10.1515/Cclm.2009.151 |
0.41 |
|
| 2009 |
Damen CW, Rosing H, Schellens JH, Beijnen JH. Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. Analytical and Bioanalytical Chemistry. 394: 1171-82. PMID 19387621 DOI: 10.1007/S00216-009-2775-Z |
0.424 |
|
| 2009 |
Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica (Stockholm, Sweden). 48: 832-41. PMID 19308757 DOI: 10.1080/02841860902806609 |
0.63 |
|
| 2009 |
Beumer JH, Franke NE, Tolboom R, Buckle T, Rosing H, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational New Drugs. 28: 145-55. PMID 19238326 DOI: 10.1007/S10637-009-9234-8 |
0.403 |
|
| 2009 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. Journal of Chromatography. A. 1216: 3168-74. PMID 19237159 DOI: 10.1016/J.Chroma.2009.02.002 |
0.377 |
|
| 2009 |
Damen CW, Israëls T, Caron HN, Schellens JH, Rosing H, Beijnen JH. Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 23: 763-74. PMID 19204931 DOI: 10.1002/Rcm.3938 |
0.452 |
|
| 2009 |
Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Journal of Pharmacokinetics and Pharmacodynamics. 36: 39-62. PMID 19199010 DOI: 10.1007/S10928-009-9111-2 |
0.652 |
|
| 2009 |
Beumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Current Clinical Pharmacology. 4: 38-42. PMID 19149499 DOI: 10.2174/157488409787236047 |
0.42 |
|
| 2009 |
Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 917-23. PMID 19139163 DOI: 10.1124/Dmd.108.024901 |
0.415 |
|
| 2009 |
Brouwers EE, Söhne M, Kuipers S, van Gorp EC, Schellens JH, Koks CH, Beijnen JH, Huitema AD. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clinical Drug Investigation. 29: 59-63. PMID 19067475 DOI: 10.2165/0044011-200929010-00006 |
0.48 |
|
| 2009 |
Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7535-44. PMID 19010872 DOI: 10.1158/1078-0432.Ccr-08-0438 |
0.418 |
|
| 2009 |
Keizer RJ, Zamacona MK, Jansen M, Critchley D, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Investigational New Drugs. 27: 140-52. PMID 18712503 DOI: 10.1007/S10637-008-9164-X |
0.649 |
|
| 2009 |
Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JH, Beijnen JH. Simultaneous Quantitative Analysis of EO9 (Apaziquone) and its Conversion Products EO5a and EO9-Cl in Human and Dog Urine by High-Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry The Open Chemical and Biomedical Methods Journal. 2: 1-12. DOI: 10.2174/1875038900902010001 |
0.443 |
|
| 2008 |
Engwegen JY, Alberts M, Knol JC, Jimenez CR, Depla AC, Tuynman H, van Heukelem HA, Snel P, Smits ME, Cats A, Schellens JH, Beijnen JH. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics. Clinical Applications. 2: 936-45. PMID 21136891 DOI: 10.1002/Prca.200780068 |
0.403 |
|
| 2008 |
Engwegen JY, Depla AC, Smits ME, Cats A, Tuynman H, van Heukelem HA, Snel P, Meuleman W, Wessels LF, Schellens JH, Beijnen JH. Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk. Biomarker Insights. 3: 375-385. PMID 19578519 DOI: 10.4137/Bmi.S790 |
0.411 |
|
| 2008 |
Sparidans RW, Vlaming ML, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 269-76. PMID 19117812 DOI: 10.1016/J.Jchromb.2008.12.026 |
0.464 |
|
| 2008 |
Schellens JH, Beijnen JH. Novel clinical trial designs for innovative therapies. Clinical Pharmacology and Therapeutics. 85: 212-6. PMID 19109591 DOI: 10.1038/Clpt.2008.247 |
0.441 |
|
| 2008 |
Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer: a review. Breast Cancer Research and Treatment. 116: 17-29. PMID 19082706 DOI: 10.1007/S10549-008-0263-3 |
0.429 |
|
| 2008 |
Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treatment Reviews. 35: 137-47. PMID 18986769 DOI: 10.1016/J.Ctrv.2008.09.004 |
0.435 |
|
| 2008 |
Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemotherapy and Pharmacology. 64: 35-43. PMID 18839173 DOI: 10.1007/S00280-008-0842-3 |
0.416 |
|
| 2008 |
Deenen MJ, Beijnen JH, Schellens JH. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4997-8; author reply. PMID 18809598 DOI: 10.1200/Jco.2008.18.8565 |
0.421 |
|
| 2008 |
Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. Bmc Clinical Pharmacology. 8: 7. PMID 18796166 DOI: 10.1186/1472-6904-8-7 |
0.644 |
|
| 2008 |
Huijbers EJ, Baars JW, Schutte PF, Schellens JH, Beijnen JH. Propofol extravasation in a breast cancer patient. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 14: 195-8. PMID 18753182 DOI: 10.1177/1078155208094454 |
0.422 |
|
| 2008 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Communications in Mass Spectrometry : Rcm. 22: 2915-28. PMID 18752334 DOI: 10.1002/Rcm.3695 |
0.448 |
|
| 2008 |
Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JH. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Molecular Cancer Therapeutics. 7: 2415-25. PMID 18723487 DOI: 10.1158/1535-7163.Mct-08-0137 |
0.42 |
|
| 2008 |
Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics. 7: 2280-7. PMID 18723475 DOI: 10.1158/1535-7163.Mct-07-2250 |
0.426 |
|
| 2008 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 872: 1-22. PMID 18701357 DOI: 10.1016/J.Jchromb.2008.07.021 |
0.389 |
|
| 2008 |
Zandvliet AS, Schellens JH, Dittrich C, Wanders J, Beijnen JH, Huitema AD. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. British Journal of Clinical Pharmacology. 66: 485-97. PMID 18637887 DOI: 10.1111/J.1365-2125.2008.03230.X |
0.663 |
|
| 2008 |
Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clinical Pharmacokinetics. 47: 487-513. PMID 18611060 DOI: 10.2165/00003088-200847080-00001 |
0.66 |
|
| 2008 |
Brouwers EE, Huitema AD, Schellens JH, Beijnen JH. The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. Anti-Cancer Drugs. 19: 621-30. PMID 18525322 DOI: 10.1097/Cad.0B013E3282Ffd6A4 |
0.596 |
|
| 2008 |
Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3477-86. PMID 18519780 DOI: 10.1158/1078-0432.Ccr-07-4521 |
0.495 |
|
| 2008 |
Appels NM, Bolijn MJ, Chan K, Stephens TC, Hoctin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, Schellens JH. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. British Journal of Cancer. 98: 1951-8. PMID 18506143 DOI: 10.1038/Sj.Bjc.6604402 |
0.524 |
|
| 2008 |
Damen CW, Rosing H, Tibben MM, van Maanen MJ, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 868: 102-9. PMID 18501686 DOI: 10.1016/J.Jchromb.2008.04.046 |
0.456 |
|
| 2008 |
Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1606-15. PMID 18490432 DOI: 10.1124/Dmd.108.021048 |
0.475 |
|
| 2008 |
Siegel-Lakhai WS, Zandvliet AS, Huitema AD, Tibben MM, Milano G, Girre V, Diéras V, King A, Richmond E, Wanders J, Beijnen JH, Schellens JH. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. British Journal of Cancer. 98: 1320-6. PMID 18414469 DOI: 10.1038/Sj.Bjc.6604300 |
0.494 |
|
| 2008 |
Meijerman I, Beijnen JH, Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treatment Reviews. 34: 505-20. PMID 18413281 DOI: 10.1016/J.Ctrv.2008.03.002 |
0.414 |
|
| 2008 |
Brouwers EE, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, Schellens JH, Beijnen JH. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Analytical and Bioanalytical Chemistry. 391: 577-85. PMID 18385987 DOI: 10.1007/S00216-008-2034-8 |
0.425 |
|
| 2008 |
Harmsen S, Koster AS, Beijnen JH, Schellens JH, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1166-71. PMID 18347084 DOI: 10.1124/Dmd.107.017335 |
0.402 |
|
| 2008 |
Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. The Oncologist. 13: 25-38. PMID 18245010 DOI: 10.1634/Theoncologist.2007-0097 |
0.364 |
|
| 2008 |
Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JH, Beijnen JH. Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically. Rapid Communications in Mass Spectrometry : Rcm. 22: 462-70. PMID 18231986 DOI: 10.1002/Rcm.3387 |
0.462 |
|
| 2007 |
Damen CW, Rosing H, Schellens JH, Beijnen JH. Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 46: 449-55. PMID 18096347 DOI: 10.1016/J.Jpba.2007.11.002 |
0.402 |
|
| 2007 |
Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Molecular Cancer Therapeutics. 6: 3307-13. PMID 18089724 DOI: 10.1158/1535-7163.Mct-07-0461 |
0.319 |
|
| 2007 |
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, ... ... Schellens JH, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical Pharmacokinetics. 46: 1051-68. PMID 18027989 DOI: 10.2165/00003088-200746120-00005 |
0.673 |
|
| 2007 |
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, ... ... Schellens JH, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6410-8. PMID 17975154 DOI: 10.1158/1078-0432.Ccr-07-0064 |
0.648 |
|
| 2007 |
Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British Journal of Clinical Pharmacology. 64: 622-33. PMID 17935602 DOI: 10.1111/J.1365-2125.2007.02956.X |
0.463 |
|
| 2007 |
Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clinical Pharmacology and Therapeutics. 83: 829-39. PMID 17851564 DOI: 10.1038/Sj.Clpt.6100344 |
0.476 |
|
| 2007 |
Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist. 12: 927-41. PMID 17766652 DOI: 10.1634/Theoncologist.12-8-927 |
0.441 |
|
| 2007 |
Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. British Journal of Cancer. 97: 577-81. PMID 17726450 DOI: 10.1038/Sj.Bjc.6603925 |
0.362 |
|
| 2007 |
Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, Koch KM, Smith DA, Pandite L, Richel DJ, Schellens JH. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4495-502. PMID 17671135 DOI: 10.1158/1078-0432.Ccr-07-0004 |
0.454 |
|
| 2007 |
Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4474-81. PMID 17671132 DOI: 10.1158/1078-0432.CCR-06-2912 |
0.333 |
|
| 2007 |
Vainchtein LD, Rosing H, Maier A, Fiebig HH, Schellens JH, Beijnen JH. Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 856: 261-6. PMID 17631060 DOI: 10.1016/J.Jchromb.2007.06.006 |
0.452 |
|
| 2007 |
Bröker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, Giaccone G. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3906-12. PMID 17606724 DOI: 10.1158/1078-0432.Ccr-06-2875 |
0.352 |
|
| 2007 |
Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 21: 2312-22. PMID 17577879 DOI: 10.1002/Rcm.3096 |
0.462 |
|
| 2007 |
Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3276-85. PMID 17545533 DOI: 10.1158/1078-0432.Ccr-06-2414 |
0.49 |
|
| 2007 |
Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JH. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2970-6. PMID 17504998 DOI: 10.1158/1078-0432.Ccr-06-2978 |
0.621 |
|
| 2007 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 854: 245-59. PMID 17500050 DOI: 10.1016/J.Jchromb.2007.04.026 |
0.435 |
|
| 2007 |
Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treatment Reviews. 33: 369-80. PMID 17451886 DOI: 10.1016/J.Ctrv.2007.02.003 |
0.458 |
|
| 2007 |
Brouwers EE, Tibben MM, Rosing H, Schellens JH, Beijnen JH. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 21: 1521-30. PMID 17410551 DOI: 10.1002/Rcm.2985 |
0.476 |
|
| 2007 |
Bosch TM, Bakker R, Schellens JH, Cats A, Smits PH, Beijnen JH. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Molecular Diagnosis & Therapy. 11: 105-8. PMID 17397246 DOI: 10.1007/Bf03256229 |
0.369 |
|
| 2007 |
Oostendorp RL, Beijnen JH, Schellens JH, Tellingen Ov. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical Chromatography : Bmc. 21: 747-54. PMID 17385801 DOI: 10.1002/Bmc.816 |
0.466 |
|
| 2007 |
Brouwers EE, Huitema AD, Bakker EN, Douma JW, Schimmel KJ, van Weringh G, de Wolf PJ, Schellens JH, Beijnen JH. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. International Archives of Occupational and Environmental Health. 80: 689-99. PMID 17377802 DOI: 10.1007/S00420-007-0181-4 |
0.401 |
|
| 2007 |
Meijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JH. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metabolism Reviews. 39: 45-60. PMID 17364880 DOI: 10.1080/03602530600952206 |
0.405 |
|
| 2007 |
Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JH. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Investigational New Drugs. 25: 327-34. PMID 17347871 DOI: 10.1007/S10637-007-9041-Z |
0.518 |
|
| 2007 |
Sparidans RW, Prins JM, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. Biomedical Chromatography : Bmc. 21: 621-7. PMID 17340566 DOI: 10.1002/bmc.797 |
0.386 |
|
| 2007 |
Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 161-72. PMID 17318195 DOI: 10.1038/Labinvest.3700503 |
0.423 |
|
| 2007 |
Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JH. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemotherapy and Pharmacology. 60: 523-33. PMID 17308894 DOI: 10.1007/S00280-006-0397-0 |
0.447 |
|
| 2007 |
Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treatment Reviews. 33: 191-202. PMID 17287087 DOI: 10.1016/J.Ctrv.2006.12.001 |
0.34 |
|
| 2007 |
Gast MC, Bonfrer JM, van Dulken EJ, de Kock L, Rutgers EJ, Schellens JH, Beijnen JH. SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. Cancer Biomarkers : Section a of Disease Markers. 2: 235-48. PMID 17264395 DOI: 10.3233/Cbm-2006-2602 |
0.406 |
|
| 2007 |
Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 60: 635-42. PMID 17205304 DOI: 10.1007/S00280-006-0405-4 |
0.482 |
|
| 2007 |
Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JH. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer Chemotherapy and Pharmacology. 59: 855-60. PMID 17180388 DOI: 10.1007/S00280-006-0334-2 |
0.416 |
|
| 2007 |
Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Molecular Pharmacology. 71: 240-9. PMID 17032904 DOI: 10.1124/Mol.106.028167 |
0.36 |
|
| 2007 |
Triesscheijn M, Ruevekamp M, Out R, Berkel TJCV, Schellens J, Baas P, Stewart FA. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men Cancer Chemotherapy and Pharmacology. 60: 113-122. PMID 17009028 DOI: 10.1007/S00280-006-0356-9 |
0.326 |
|
| 2007 |
Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, Schellens JH, Beijnen JH. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. Journal of Pharmaceutical and Biomedical Analysis. 43: 285-92. PMID 16920321 DOI: 10.1016/J.Jpba.2006.06.044 |
0.445 |
|
| 2007 |
Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH, Schellens JH. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Investigational New Drugs. 25: 9-19. PMID 16633717 DOI: 10.1007/S10637-006-7589-7 |
0.45 |
|
| 2007 |
Beumer JH, Buckle T, Ouwehand M, Franke NE, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Investigational New Drugs. 25: 1-7. PMID 16633714 DOI: 10.1007/S10637-006-7773-9 |
0.401 |
|
| 2007 |
Appels NM, Rosing H, Stephens TC, Schellens JH, Beijnen JH. Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: pharmacodynamic assay for farnesyl transferase inhibitors. Analytical Chemistry. 78: 2617-22. PMID 16615771 DOI: 10.1021/Ac051786S |
0.473 |
|
| 2007 |
Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C -Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer Clinical Cancer Research. 13: 4474-4481. DOI: 10.1158/1078-0432.Ccr-06-2912 |
0.49 |
|
| 2007 |
Sparidans RW, Prins JM, Schellens JH, Beijnen JH. Liquid chromatography–tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma Biomedical Chromatography. 21: 621-627. DOI: 10.1002/Bmc.797 |
0.472 |
|
| 2006 |
Kuppens IE, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, Schellens JH. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. Investigational New Drugs. 25: 227-35. PMID 17146730 DOI: 10.1007/S10637-006-9027-2 |
0.478 |
|
| 2006 |
Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5786-93. PMID 17020985 DOI: 10.1158/1078-0432.Ccr-05-2649 |
0.644 |
|
| 2006 |
Siegel-Lakhai WS, Crul M, De Porre P, Zhang S, Chang I, Boot H, Beijnen JH, Schellens JH. Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4558-64. PMID 17008695 DOI: 10.1200/Jco.2006.05.8123 |
0.448 |
|
| 2006 |
Beumer JH, Rademaker-Lakhai JM, Rosing H, Hillebrand MJ, Bosch TM, Lopez-Lazaro L, Schellens JH, Beijnen JH. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 59: 825-37. PMID 16988825 DOI: 10.1007/s00280-006-0342-2 |
0.371 |
|
| 2006 |
Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. Journal of Mass Spectrometry : Jms. 41: 1268-76. PMID 16981212 DOI: 10.1002/Jms.1086 |
0.457 |
|
| 2006 |
Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. British Journal of Cancer. 95: 794-800. PMID 16969354 DOI: 10.1038/Sj.Bjc.6603332 |
0.5 |
|
| 2006 |
Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. Journal of Pharmacokinetics and Pharmacodynamics. 33: 543-70. PMID 16946998 DOI: 10.1007/S10928-006-9021-5 |
0.644 |
|
| 2006 |
Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of Mass Spectrometry : Jms. 41: 1186-94. PMID 16929560 DOI: 10.1002/Jms.1087 |
0.468 |
|
| 2006 |
Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. British Journal of Cancer. 95: 729-34. PMID 16926835 DOI: 10.1038/Sj.Bjc.6603312 |
0.481 |
|
| 2006 |
Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & Clinical Pharmacology & Toxicology. 99: 133-40. PMID 16918714 DOI: 10.1111/J.1742-7843.2006.Pto_309.X |
0.488 |
|
| 2006 |
Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 80: 207-13. PMID 16914220 DOI: 10.1016/J.Radonc.2006.07.032 |
0.448 |
|
| 2006 |
Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. The Oncologist. 11: 742-52. PMID 16880233 DOI: 10.1634/Theoncologist.11-7-742 |
0.457 |
|
| 2006 |
Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British Journal of Clinical Pharmacology. 62: 71-80. PMID 16842380 DOI: 10.1111/J.1365-2125.2005.02513.X |
0.455 |
|
| 2006 |
Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. Biomedical Chromatography : Bmc. 20: 671-3. PMID 16799929 DOI: 10.1002/Bmc.667 |
0.64 |
|
| 2006 |
Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. European Journal of Clinical Pharmacology. 62: 681-4. PMID 16799820 DOI: 10.1007/S00228-006-0162-7 |
0.386 |
|
| 2006 |
Boekhout AH, Beijnen JH, Schellens JH. Symptoms and treatment in cancer therapy-induced early menopause. The Oncologist. 11: 641-54. PMID 16794243 DOI: 10.1634/Theoncologist.11-6-641 |
0.411 |
|
| 2006 |
van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treatment Reviews. 32: 390-7. PMID 16781082 DOI: 10.1016/J.Ctrv.2006.04.011 |
0.415 |
|
| 2006 |
Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonneterre ME, Beijnen JH, Schellens JH, Bonneterre J. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3774-81. PMID 16778105 DOI: 10.1158/1078-0432.Ccr-05-2368 |
0.484 |
|
| 2006 |
Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Molecular Diagnosis & Therapy. 10: 175-85. PMID 16771603 DOI: 10.1007/Bf03256456 |
0.425 |
|
| 2006 |
van den Broek I, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 837: 49-58. PMID 16713406 DOI: 10.1016/J.Jchromb.2006.03.059 |
0.457 |
|
| 2006 |
Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Cancer Chemotherapy and Pharmacology. 59: 43-50. PMID 16680462 DOI: 10.1007/S00280-006-0245-2 |
0.435 |
|
| 2006 |
Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. The Journal of Pharmacology and Experimental Therapeutics. 318: 319-27. PMID 16611851 DOI: 10.1124/Jpet.106.101774 |
0.437 |
|
| 2006 |
Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2150-7. PMID 16609028 DOI: 10.1158/1078-0432.Ccr-05-2069 |
0.658 |
|
| 2006 |
Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends in Pharmacological Sciences. 27: 251-9. PMID 16600386 DOI: 10.1016/J.Tips.2006.03.003 |
0.407 |
|
| 2006 |
Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH, Meijerman I. Screening for polymorphisms in the PXR gene in a Dutch population. European Journal of Clinical Pharmacology. 62: 395-9. PMID 16568343 DOI: 10.1007/S00228-006-0108-0 |
0.371 |
|
| 2006 |
Zandvliet AS, Copalu W, Schellens JH, Beijnen JH, Huitema AD. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1041-6. PMID 16565173 DOI: 10.1124/Dmd.105.008326 |
0.614 |
|
| 2006 |
Appels NM, Rosing H, Stephens TC, Hughes A, Schellens JH, Beijnen JH. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. Analytical Biochemistry. 352: 33-40. PMID 16564488 DOI: 10.1016/J.Ab.2006.02.028 |
0.413 |
|
| 2006 |
Vink SR, Lagerwerf S, Mesman E, Schellens JH, Begg AC, van Blitterswijk WJ, Verheij M. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1615-22. PMID 16533789 DOI: 10.1158/1078-0432.Ccr-05-2033 |
0.309 |
|
| 2006 |
Sparidans RW, Bosch TM, Jörger M, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 839: 45-53. PMID 16513432 DOI: 10.1016/J.Jchromb.2006.02.016 |
0.452 |
|
| 2006 |
Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clinical Pharmacokinetics. 45: 253-85. PMID 16509759 DOI: 10.2165/00003088-200645030-00003 |
0.47 |
|
| 2006 |
Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, Schellens JH. Relationship between cisplatin administration and the development of ototoxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 918-24. PMID 16484702 DOI: 10.1200/JCO.2006.10.077 |
0.346 |
|
| 2006 |
Beumer JH, Beijnen JH, Schellens JH. Mass balance studies, with a focus on anticancer drugs. Clinical Pharmacokinetics. 45: 33-58. PMID 16430310 DOI: 10.2165/00003088-200645010-00003 |
0.489 |
|
| 2006 |
Brandon EF, Sparidans RW, Guijt KJ, Löwenthal S, Meijerman I, Beijnen JH, Schellens JH. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Investigational New Drugs. 24: 3-14. PMID 16379042 DOI: 10.1007/S10637-005-4538-9 |
0.42 |
|
| 2006 |
Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). The Oncologist. 10: 579-89. PMID 16177282 DOI: 10.1634/Theoncologist.10-8-579 |
0.401 |
|
| 2006 |
Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. The Oncologist. 10: 565-78. PMID 16177281 DOI: 10.1634/Theoncologist.10-8-565 |
0.426 |
|
| 2006 |
Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JH, Beijnen JH. A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomedical Chromatography : Bmc. 20: 139-48. PMID 16041788 DOI: 10.1002/Bmc.544 |
0.465 |
|
| 2006 |
Appels NM, Tung KO, Rosing H, Schellens JH, Beijnen JH. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors. Biomedical Chromatography : Bmc. 20: 161-5. PMID 16032760 DOI: 10.1002/Bmc.545 |
0.402 |
|
| 2006 |
Brandon EF, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JB, Bijl M, Beijnen JH, Schellens JH, Meijerman I. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. Toxicology and Applied Pharmacology. 211: 1-10. PMID 15975613 DOI: 10.1016/J.Taap.2005.05.004 |
0.418 |
|
| 2006 |
Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomedical Chromatography : Bmc. 20: 72-6. PMID 15954163 DOI: 10.1002/Bmc.530 |
0.652 |
|
| 2006 |
Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JH, Beijnen JH, Smits PH, Meijerman I. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 5: 123-31. PMID 15813675 DOI: 10.2165/00129785-200505020-00005 |
0.428 |
|
| 2006 |
Bosch T, Meijerman I, Beijnen J, Schellens J. Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk Current Cancer Therapy Reviews. 2: 137-155. DOI: 10.2174/157339406776872825 |
0.412 |
|
| 2006 |
Beerepoot L, Rademaker-Lakhai J, Witteveen E, Radema S, Viseren-Grul C, Musib L, Van Hal J, Beijnen J, Schellens J, Voest E. Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer Journal of Clinical Oncology. 24: 2046-2046. DOI: 10.1200/jco.2006.24.18_suppl.2046 |
0.382 |
|
| 2006 |
Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, Schellens JH. Relationship Between Cisplatin Administration and the Development of Ototoxicity Journal of Clinical Oncology. 24: 918-924. DOI: 10.1200/Jco.2006.10.077 |
0.458 |
|
| 2005 |
Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends in Pharmacological Sciences. 27: 17-24. PMID 16337012 DOI: 10.1016/J.Tips.2005.11.009 |
0.46 |
|
| 2005 |
Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, Schellens JH. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British Journal of Cancer. 93: 1222-9. PMID 16251868 DOI: 10.1038/Sj.Bjc.6602850 |
0.491 |
|
| 2005 |
Kuppens IE, Breedveld P, Beijnen JH, Schellens JH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Investigation. 23: 443-64. PMID 16193644 DOI: 10.1081/Cnv-58823 |
0.446 |
|
| 2005 |
Rademaker-Lakhai JM, Crul M, Pluim D, Sparidans RW, Baas P, Beijnen JH, van Zandwijk N, Schellens JH. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs. 16: 1029-36. PMID 16162981 DOI: 10.1097/01.Cad.0000176507.78928.4D |
0.491 |
|
| 2005 |
Brandon EF, Meijerman I, Klijn JS, den Arend D, Sparidans RW, Lázaro LL, Beijnen JH, Schellens JH. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anti-Cancer Drugs. 16: 935-43. PMID 16162970 DOI: 10.1097/01.Cad.0000180121.16407.38 |
0.439 |
|
| 2005 |
Beumer JH, Hillebrand MJ, Pluim D, Rosing H, Foley K, Yule SM, Schellens JH, Beijnen JH. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Investigational New Drugs. 23: 317-30. PMID 16012791 DOI: 10.1007/S10637-005-1440-4 |
0.476 |
|
| 2005 |
Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Investigational New Drugs. 23: 279-86. PMID 16012787 DOI: 10.1007/S10637-005-1436-0 |
0.379 |
|
| 2005 |
Appels NM, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 19: 2187-92. PMID 15996016 DOI: 10.1002/Rcm.2046 |
0.481 |
|
| 2005 |
Brouwers EE, Tibben MM, Joerger M, van Tellingen O, Rosing H, Schellens JH, Beijnen JH. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry. 382: 1484-90. PMID 15952001 DOI: 10.1007/S00216-005-3302-5 |
0.447 |
|
| 2005 |
Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JH, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anti-Cancer Drugs. 16: 627-30. PMID 15930890 DOI: 10.1097/00001813-200507000-00006 |
0.667 |
|
| 2005 |
Brandon EF, van Ooijen RD, Sparidans RW, Lázaro LL, Heck AJ, Beijnen JH, Schellens JH. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. Journal of Mass Spectrometry : Jms. 40: 821-31. PMID 15892174 DOI: 10.1002/Jms.863 |
0.42 |
|
| 2005 |
van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, ... ... Schellens JH, et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investigational New Drugs. 23: 225-34. PMID 15868378 DOI: 10.1007/S10637-005-6730-3 |
0.779 |
|
| 2005 |
Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JH, van Tellingen O. Metabolism of docetaxel in mice. Cancer Chemotherapy and Pharmacology. 56: 299-306. PMID 15864592 DOI: 10.1007/S00280-004-0945-4 |
0.405 |
|
| 2005 |
van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CM, Schellens JH, Beijnen JH, Schinkel AH. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 892-5. PMID 15845749 DOI: 10.1124/Dmd.105.004721 |
0.44 |
|
| 2005 |
de Maat MM, Beijnen JH, Schellens JH, Mulder JW. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. The Journal of Infection. 50: 262-4. PMID 15780424 DOI: 10.1016/J.Jinf.2004.02.011 |
0.446 |
|
| 2005 |
Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1854-62. PMID 15756010 DOI: 10.1158/1078-0432.Ccr-04-1534 |
0.442 |
|
| 2005 |
Beumer JH, Schellens JH, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacological Research. 51: 391-8. PMID 15749453 DOI: 10.1016/J.Phrs.2004.12.001 |
0.427 |
|
| 2005 |
Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemotherapy and Pharmacology. 55: 488-96. PMID 15726371 DOI: 10.1007/S00280-004-0900-4 |
0.492 |
|
| 2005 |
van Tellingen O, Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JH. Cannulation of the jugular vein in mice. Laboratory Animals. 39: 130. PMID 15703135 DOI: 10.1258/0023677052886466 |
0.321 |
|
| 2005 |
Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 55: 263-70. PMID 15592838 DOI: 10.1007/S00280-004-0874-2 |
0.493 |
|
| 2005 |
Kuppens IE, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography : Bmc. 19: 355-61. PMID 15586372 DOI: 10.1002/Bmc.457 |
0.456 |
|
| 2005 |
Stokvis E, Rosing H, López-Lázaro L, Schellens JH, Beijnen JH. A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. Biomedical Chromatography : Bmc. 18: 403-7. PMID 15273982 DOI: 10.1002/Bmc.404 |
0.469 |
|
| 2004 |
Lakhai WS, Beijnen JH, Den Boer SS, Westermann AM, Versola M, Koch K, Ho P, Pandite L, Richel DJ, Schellens J. Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2044. PMID 28015625 DOI: 10.1200/Jco.2004.22.14_Suppl.2044 |
0.449 |
|
| 2004 |
Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods and Findings in Experimental and Clinical Pharmacology. 26: 531-45. PMID 15538543 DOI: 10.1358/Mf.2004.26.7.863736 |
0.486 |
|
| 2004 |
Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7220-8. PMID 15534095 DOI: 10.1158/1078-0432.Ccr-04-0452 |
0.382 |
|
| 2004 |
Beumer JH, Rosing H, Hillebrand MJ, Nan-Offeringa LG, Foley K, Yule SM, Heck AJ, Schellens JH, Beijnen JH. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 18: 2839-48. PMID 15517526 DOI: 10.1002/Rcm.1699 |
0.483 |
|
| 2004 |
Stokvis E, Rosing H, Causon RC, Schellens JH, Beijnen JH. Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection. Journal of Mass Spectrometry : Jms. 39: 1122-30. PMID 15468145 DOI: 10.1002/Jms.687 |
0.461 |
|
| 2004 |
Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, ... ... Schellens JH, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. British Journal of Cancer. 91: 1434-41. PMID 15381932 DOI: 10.1038/Sj.Bjc.6602172 |
0.454 |
|
| 2004 |
Kuppens IE, Beijnen J, Schellens JH. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clinical Colorectal Cancer. 4: 163-80. PMID 15377400 DOI: 10.3816/ccc.2004.n.017 |
0.398 |
|
| 2004 |
Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemotherapy and Pharmacology. 55: 72-8. PMID 15316750 DOI: 10.1007/S00280-004-0864-4 |
0.431 |
|
| 2004 |
Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Research. 64: 5804-11. PMID 15313923 DOI: 10.1158/0008-5472.Can-03-4062 |
0.421 |
|
| 2004 |
Beijnen JH, Schellens JH. Drug interactions in oncology. The Lancet. Oncology. 5: 489-96. PMID 15288238 DOI: 10.1016/S1470-2045(04)01528-1 |
0.437 |
|
| 2004 |
Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P, Schellens JH. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4072-6. PMID 15217941 DOI: 10.1158/1078-0432.Ccr-1076-03 |
0.423 |
|
| 2004 |
Stokvis E, Nan-Offeringa LG, Ouwehand M, Tibben MM, Rosing H, Schnaars Y, Grigat M, Romeis P, Schellens JH, Beijnen JH. Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 18: 1465-71. PMID 15216507 DOI: 10.1002/Rcm.1493 |
0.457 |
|
| 2004 |
Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3717-27. PMID 15173078 DOI: 10.1158/1078-0432.Ccr-03-0746 |
0.475 |
|
| 2004 |
Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3386-95. PMID 15161693 DOI: 10.1158/1078-0432.Ccr-03-0315 |
0.432 |
|
| 2004 |
Kerbusch T, Groenewegen G, Mathôt RA, Herben VM, ten Bokkel Huinink WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, Schellens JH. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. British Journal of Cancer. 90: 2268-77. PMID 15150579 DOI: 10.1038/Sj.Bjc.6601861 |
0.449 |
|
| 2004 |
Brandon EF, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, Schellens JH. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Investigational New Drugs. 22: 241-51. PMID 15122071 DOI: 10.1023/B:Drug.0000026250.34645.7F |
0.446 |
|
| 2004 |
Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Investigational New Drugs. 22: 219-29. PMID 15122069 DOI: 10.1023/B:Drug.0000026248.45084.21 |
0.443 |
|
| 2004 |
Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 38: e73-5. PMID 15095234 DOI: 10.1086/382675 |
0.627 |
|
| 2004 |
de Jonge ME, van den Bongard HJ, Huitema AD, Mathôt RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, Schellens JH. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2237-44. PMID 15073098 DOI: 10.1158/1078-0432.Ccr-03-0060 |
0.782 |
|
| 2004 |
Stokvis E, Rosing H, Crul M, Rieser MJ, Heck AJ, Schellens JH, Beijnen JH. Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. Journal of Mass Spectrometry : Jms. 39: 277-88. PMID 15039935 DOI: 10.1002/Jms.579 |
0.499 |
|
| 2004 |
Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemotherapy and Pharmacology. 54: 71-8. PMID 15034754 DOI: 10.1007/S00280-004-0773-6 |
0.386 |
|
| 2004 |
Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J. Capecitabine induces severe angina-like chest pain. Annals of Internal Medicine. 140: 494-5. PMID 15023730 DOI: 10.7326/0003-4819-140-6-200403160-00034 |
0.319 |
|
| 2004 |
Sparidans RW, Schellens JH, López-Lázaro L, Jimeno JM, Beijnen JH. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. Biomedical Chromatography : Bmc. 18: 16-20. PMID 14872544 DOI: 10.1002/Bmc.286 |
0.443 |
|
| 2004 |
van den Bongard HJ, Kemper EM, van Tellingen O, Rosing H, Mathôt RA, Schellens JH, Beijnen JH. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Analytical Biochemistry. 324: 11-5. PMID 14654039 DOI: 10.1016/J.Ab.2003.07.024 |
0.618 |
|
| 2004 |
Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3526-33. PMID 14506138 |
0.361 |
|
| 2004 |
Sparidans RW, Crommentuyn KM, Schellens JH, Beijnen JH. Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 791: 227-33. PMID 12798182 DOI: 10.1016/S1570-0232(03)00225-3 |
0.449 |
|
| 2004 |
Kuppens IE, Beijnen JH, Schellens JH. Topoisomerase I Inhibitors in the Treatment of Gastrointestinal Cancer: From Intravenous to Oral Administration Clinical Colorectal Cancer. 4: 163-180. DOI: 10.3816/Ccc.2004.N.017 |
0.481 |
|
| 2004 |
Gast M, Bonfrer J, Rutgers E, Schellens J, Beijnen J. New discriminatory serum protein profiles in breast cancer patients Journal of Clinical Oncology. 22: 574-574. DOI: 10.1200/Jco.2004.22.90140.574 |
0.427 |
|
| 2003 |
Sparidans RW, Silvertand L, Dost F, Rothbarth J, Mulder GJ, Schellens JH, Beijnen JH. Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. Biomedical Chromatography : Bmc. 17: 458-64. PMID 14598330 DOI: 10.1002/Bmc.273 |
0.428 |
|
| Show low-probability matches. |
